Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist

被引：2

作者：

Baska, Ferenc ^{[1
]}

Bozo, Eva ^{[1
]}

Szeleczky, Zsolt ^{[1
]}

Szanto, Gabor ^{[1
]}

Vukics, Krisztina ^{[1
]}

Szakacs, Zoltan ^{[1
]}

Domany-Kovacs, Katalin ^{[1
]}

Kurko, Dalma ^{[1
]}

Vass, Elemer ^{[2
]}

Than, Marta ^{[1
]}

Vastag, Monika ^{[1
]}

Temesvari, Krisztina ^{[1
]}

Levai, Sandor ^{[1
]}

Halasz, Attila Sandor ^{[1
]}

Kordas, Krisztina Szondine ^{[1
]}

Roman, Viktor ^{[1
]}

Greiner, Istvan ^{[1
]}

Bata, Imre ^{[1
]}

机构：

[1] Gedeon Richter Plc, H-1475 Budapest, Hungary

[2] Eotvos Lorand Univ, Inst Chem, H-1117 Budapest, Hungary

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2024年 / 67卷 / 01期

关键词：

RANDOMIZED CONTROLLED-TRIAL; AUTISM SPECTRUM DISORDERS; VASOPRESSIN V1A; ACTIVE METABOLITE; BALOVAPTAN; PHARMACOKINETICS; PAZINACLONE; INHIBITION; SR-49059; SINGLE;

D O I：

10.1021/acs.jmedchem.3c01868

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The V1a receptor is a major contributor in mediating the social and emotional effects of arginine-vasopressin (AVP); therefore it represents a promising target in the treatment of several neuropsychiatric conditions. The aim of this research was to design and synthesize novel and selective V1a antagonists with improved in vitro and in vivo profiles. Through optimization and detailed SAR studies, we developed low nanomolar antagonists, and further characterizations led to the discovery of the clinical candidate compound 43 (RGH-122). The CNS activity of the compound was determined in a 3-chamber social preference test of autism in which RGH-122 successfully enhanced social preference with the lowest effective dose of 1.5 mg/kg.

引用

页码：643 / 673

页数：31

共 50 条

[31] Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1
Dow, Robert L.
Li, Jian-Cheng
Pence, Michael P.
Gibbs, E. Michael
LaPerle, Jennifer L.
Litchfield, John
Piotrowski, David W.
Munchhof, Michael J.
Manion, Tara B.
Zavadoski, William J.
Walker, Gregory S.
McPherson, R. Kirk
Tapley, Susan
Sugarman, Eliot
Guzman-Perez, Angel
DaSilva-Jardine, Paul
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (05): : 407 - 412
[32] Discovery and characterization of a potent and selective EP4 receptor antagonist
Schiffler, Matthew A.
Chandrasekhar, Srinivasan
Fisher, Matthew J.
Harvey, Anita
Kuklish, Steven L.
Wang, Xu-Shan
Warshawsky, Alan M.
York, Jeremy S.
Yu, Xiao-Peng
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (16) : 3176 - 3178
[33] Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5
Carter, Percy H.
Brown, Gregory D.
Cherney, Robert J.
Batt, Douglas G.
Chen, Jing
Clark, Cheryl M.
Cvijic, Mary Ellen
Duncia, John V.
Ko, Soo S.
Mandlekar, Sandhya
Mo, Ruowei
Nelson, David J.
Pang, Jian
Rose, Anne V.
Santella, Joseph B., III
Tebben, Andrew J.
Traeger, Sarah C.
Xu, Songmei
Zhao, Qihong
Barrish, Joel C.
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (04): : 439 - 444
[34] Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable γ-Secretase Modulator
Peng, Hairuo
Talreja, Tina
Xin, Zhili
Cuervo, J. Hernan
Kumaravel, Gnanasambandam
Humora, Michael J.
Xu, Lin
Rohde, Ellen
Gan, Lawrence
Jung, Mi-young
Shackett, Melanie N.
Chollate, Sowmya
Dunah, Anthone W.
Snodgrass-belt, Pamela A.
Arnold, H. Moore
Taveras, Arthur G.
Rhodes, Kenneth J.
Scannevin, Robert H.
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (10): : 786 - 791
[35] Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors
Qin, Donghui
Lin, Xiaojuan
Liu, Zhi
Chen, Yan
Zhang, Zhiliu
Wu, Chengde
Liu, Linlin
Pan, Yan
Laquerre, Sylvie
Emery, John
Fergusson, Jeff
Roland, Kimberly
Keenan, Rick
Oliff, Allen
Kumar, Sanjay
Cheung, Mui
Su, Dai-Shi
ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (06): : 1005 - 1010
[36] Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors
Duan, James J. -W.
Chen, Lihua
Lu, Zhonghui
Xue, Chu-Biao
Liu, Rui-Qin
Covington, Maryanne B.
Qian, Mingxin
Wasserman, Zelda R.
Vaddi, Krishna
Christ, David D.
Trzaskos, James M.
Newton, Robert C.
Decicco, Carl P.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (01) : 241 - 246
[37] Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist
Xue, Chu-Biao
Wang, Anlai
Han, Qi
Zhang, Yingxin
Cao, Ganfeng
Feng, Hao
Huang, Taisheng
Zheng, Changsheng
Xia, Michael
Zhang, Ke
Kong, Lingquan
Glenn, Joseph
Anand, Rajan
Meloni, David
Robinson, D. J.
Shao, Lixin
Storace, Lou
Li, Mei
Hughes, Robert O.
Devraj, Rajesh
Morton, Philip A.
Rogier, D. Joseph
Covington, Maryanne
Scherle, Peggy
Diamond, Sharon
Emm, Tom
Yeleswaram, Swamy
Contel, Nancy
Vaddi, Kris
Newton, Robert
Hollis, Greg
Metcalf, Brian
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (12): : 913 - 918
[38] Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors
Cheng, Dai
Liu, Jun
Han, Dong
Zhang, Guobao
Gao, Wenqi
Hsieh, Mindy H.
Ng, Nicholas
Kasibhatla, Shailaja
Tompkins, Celin
Li, Jie
Steffy, Auzon
Sun, Fangxian
Li, Chun
Seidel, H. Martin
Harris, Jennifer L.
Pan, Shifeng
ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (07): : 676 - 680
[39] Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists
Ibrahim, Mohamed A.
Johnson, Henry W. B.
Jeong, Joon Won
Lewis, Gary L.
Shi, Xian
Noguchi, Robin T.
Williams, Matthew
Leahy, James W.
Nuss, John M.
Woolfrey, John
Banica, Monica
Bentzien, Frauke
Chou, Yu-Chien
Gibson, Anna
Heald, Nathan
Lamb, Peter
Mattheakis, Larry
Matthews, David
Shipway, Aaron
Wu, Xiang
Zhang, WenTao
Zhou, Sihong
Shankar, Geetha
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 1368 - 1381
[40] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
Tahara, A
Saito, M
Sugimoto, T
Tomura, Y
Wada, K
Kusayama, T
Tsukada, J
Ishii, N
Yatsu, T
Uchida, W
Tanaka, A
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69

← 1 2 3 4 5 →